Register entry
Salix Pharmaceuticals, Inc.
- Registered sites
- 0
- Drug products
- 16
- Live patents
- 71
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
71Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| APRISO | MESALAMINE | May 2030 |
| OSMOPREP | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | Jun 2028 |
| PLENVU | ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE | Mar 2032 |
| PLENVU | ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE | Mar 2032 |
| PLENVU | ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE | Aug 2032 |
| PLENVU | ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE | Sept 2033 |
| RELISTOR | METHYLNALTREXONE BROMIDE | Aug 2027 |
| RELISTOR | METHYLNALTREXONE BROMIDE | Sept 2029 |
| RELISTOR | METHYLNALTREXONE BROMIDE | Dec 2030 |
| RELISTOR | METHYLNALTREXONE BROMIDE | Mar 2031 |
| TRULANCE | PLECANATIDE | Jan 2028 |
| TRULANCE | PLECANATIDE | Sept 2031 |
| TRULANCE | PLECANATIDE | Mar 2032 |
| TRULANCE | PLECANATIDE | Aug 2032 |
| TRULANCE | PLECANATIDE | Jun 2034 |
| UCERIS | BUDESONIDE | Sept 2031 |
| XIFAXAN | RIFAXIMIN | Sept 2027 |
| XIFAXAN | RIFAXIMIN | Feb 2029 |
| XIFAXAN | RIFAXIMIN | Jul 2029 |
| XIFAXAN | RIFAXIMIN | Oct 2029 |
Catalogue
Marketed products
16Showing 16 of 16.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| APRISO | mesalamine | CAPSULE, EXTENDED RELEASE | NDA |
| Anusol HC | hydrocortisone | CREAM | ANDA |
| Anusol HC | HYDROCORTISONE ACETATE | SUPPOSITORY | UNAPPROVED DRUG OTHER |
| Azasan | Azathioprine | TABLET | ANDA |
| Azasan | Azathioprine | TABLET | ANDA |
| DIURIL | CHLOROTHIAZIDE | SUSPENSION | NDA |
| MoviPrep | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE | KIT | NDA |
| Plenvu | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE | KIT | NDA |
| Proctocort | HYDROCORTISONE ACETATE | SUPPOSITORY | UNAPPROVED DRUG OTHER |
| Relistor | Methylnaltrexone bromide | TABLET | NDA |
| Relistor | Methylnaltrexone bromide | INJECTION, SOLUTION | NDA |
| Relistor | Methylnaltrexone bromide | INJECTION, SOLUTION | NDA |
| Trulance Immediate release | Plecanatide | TABLET | NDA |
| Uceris | budesonide | AEROSOL, FOAM | NDA |
| XIFAXAN | rifaximin | TABLET | NDA |
| XIFAXAN | rifaximin | TABLET | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.